Lipocine Inc. (NASDAQ: LPCN) disclosed that its Chief Executive Officer and Director, Mahesh V. Patel, acquired shares of the company's common stock in two separate transactions on November 12 and November 13, 2026. The total value of the purchases was $79,487.
According to the filings, Patel bought 25,000 shares on each of the two days. The prices paid ranged from $1.5796 to $1.5999 per share. Following these transactions, Patel's direct beneficial ownership in Lipocine common stock stands at 211,495 shares.
The insider buying comes as Lipocine's stock trades at $1.71, reflecting a year-to-date decline of 78.7%. Despite the sharp drop, some analyst commentary suggests the company is currently undervalued. Analysts predict the company will be profitable this year, with earnings per share forecast at $4.46 for fiscal 2026. The company also maintains a strong balance sheet, holding more cash than debt.
In other recent developments, Lipocine announced the initiation of its Phase 3 BLOOM trial for LPCN1154, a treatment aimed at severe postpartum depression. The company plans to begin dosing the first participant in the early fourth quarter of 2026. Following this announcement, H.C. Wainwright maintained a Neutral rating on Lipocine with a price target of $4.00.
Additionally, Lipocine updated its sales agent fee agreement with A.G.P./Alliance Global Partners. The revised agreement states that the fee for sales under the existing Sales Agreement will be up to 3.0%. This update was formalized in a recent SEC filing and is subject to adjustment by mutual agreement between Lipocine and the sales agent.
These developments reflect ongoing strategic and operational activities within the company.